Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

This study demonstrates the real-world effectiveness of mepolizumab in achieving clinical remission and sustained remission in severe eosinophilic asthma over 24 months. The identification of distinct factors associated with the likelihood of achieving clinical remission emphasizes the importance of comprehensive management of comorbidities and timely identification of patients who may benefit from biologics.

Authors

Institutions

Publication Details

Journal
The Journal of Allergy and Clinical Immunology In Practice
Published
2024-08-26
DOI
https://doi.org/10.1016/j.jaip.2024.08.033
Citations
33
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
10.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

Nunzio Crimi, Nicola Scichilone, Maria D’Amato, Maria Pia Foschino Barbaro et al.
33 citations
The Journal of Allergy and Clinical Immunology In Practice
Asthma and respiratory diseases
10.78
article

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

Nunzio Crimi, Nicola Scichilone, Maria D’Amato, Maria Pia Foschino Barbaro, Maria Filomena Caiaffa, Girolamo Pelaia, Luigi Ciampo, Carolina Vitale, Raffaele Campisi, Giulia Scioscia, Claudia Crimi, Corrado Pelaia, Cecilia Calabrese, Alberto Noto, Santi Nolasco, Federica Massaro, Giuseppe Valenti, Massimo Triggiani, Vitaliano Nicola Quaranta, Angelantonio Maglio, Giovanna Elisiana Carpagnano, Danilo Di Bona, Silvano Dragonieri, Elena Minenna, Francesco Papia, Alessandro Vatrella, Luigi Macchia, Lorena Gallotti
article en
33 citations

Abstract

This study demonstrates the real-world effectiveness of mepolizumab in achieving clinical remission and sustained remission in severe eosinophilic asthma over 24 months. The identification of distinct factors associated with the likelihood of achieving clinical remission emphasizes the importance of comprehensive management of comorbidities and timely identification of patients who may benefit from biologics.

The Journal of Allergy and Clinical Immunology In PracticeVol. 12(12)
University of Foggia (IT), University of Messina (IT), University of Salerno (IT), University of Campania "Luigi Vanvitelli" (IT), Marconi University (IT), Magna Graecia University (IT), University of Catania (IT), Neuroscience Institute (IT), Istituto Ortopedico Gaetano Pini (IT), Policlinico Universitario di Catania (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Palermo (IT)
AstraZeneca, Sanofi, Università degli Studi di Napoli Federico II, McMaster University, ResMed, Università di Catania, Università degli Studi di Palermo, Università degli Studi di Salerno, Università degli Studi di Messina
Good health and well-being
Openalex Percentile: Top 1%
Asthma and respiratory diseases
10.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.